LYTIX BIOPHARMA ASA: årsregnskap 2014 vs 2013
Grew 12718% on revenue, cash halved-plus, fresh owner capital
approved 2015-04-30; registry 2015-06-20; journal 2015 493342
Summary
What changed
Comparing Årsregnskap 2014 with 2013 for LYTIX BIOPHARMA ASA. Revenue 50.2k NOK → 6.44m NOK (+12718.1%). Equity 47.22m NOK → 59.65m NOK.
On the constructive side: revenue rose; operating result improved; equity strengthened. Pressures included: cash fell.
Also worth watching: sharp cash drawdown; book investments changed. All figures are taken from the published annual accounts for LYTIX BIOPHARMA ASA.
At a glance
Scorecard
What improved
-
↑
Revenue rose
Operating income / revenue moved from 50.2k NOK to 6.44m NOK (+12718.1% YoY). Calculated
-
↑
Operating result improved
Operating result -43.44m NOK → -40.10m NOK (op. margin -86449.1% → -622.6%). Calculated
-
↑
Equity strengthened
Book equity 47.22m NOK → 59.65m NOK (equity ratio 81.3% → 82.7%). Calculated
-
↑
Owners injected capital
Paid-in equity rose 47.22m NOK → 59.65m NOK (+12.44m NOK). Reported fact
What deteriorated
-
↓
Cash fell
Bank deposits 51.47m NOK → 9.08m NOK (-82.4% YoY). Calculated
Things to notice
-
·
Sharp cash drawdown
Cash fell by more than 60% YoY (51.47m NOK → 9.08m NOK). Check whether funds moved to group receivables, investments, or operating burn. Interpretation
-
·
Book investments changed
Investment / intangible book value 0 NOK → 5 600 NOK. Reported fact